ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e18690
Abstract: e18690Background: CABOSUN, a randomized and open-label phase II trial, demonstrated significant improvement in progression-free survival (PFS) with cabozantinib versus sunitinib in the first-line t... read more here.
Keywords: score analysis; trial; health related; proxy health ... See more keywords